Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies
The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.
You may also be interested in...
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.